US 11,952,578 B2
Compositions and methods for site directed genomic modification
Brent Brower-Toland, St. Louis, MO (US); Andrei Y. Kouranov, Chesterfield, MO (US); Rosemarie Kuehn, St. Louis, MO (US); Richard J. Lawrence, Kirkwood, MO (US); Ervin D. Nagy, Lake St. Louis, MO (US); Linda Rymarquis, High Ridge, MO (US); and Veena Veena, St. Louis, MO (US)
Assigned to Monsanto Technology LLC, St. Louis, MO (US)
Filed by Monsanto Technology LLC, St. Louis, MO (US)
Filed on Dec. 26, 2022, as Appl. No. 18/146,434.
Application 18/146,434 is a division of application No. 17/503,235, filed on Oct. 15, 2021, granted, now 11,566,254.
Application 17/503,235 is a division of application No. 15/120,110, granted, now 11,186,843, issued on Nov. 30, 2021, previously published as PCT/US2015/018104, filed on Feb. 27, 2015.
Claims priority of provisional application 61/945,700, filed on Feb. 27, 2014.
Prior Publication US 2023/0212596 A1, Jul. 6, 2023
Int. Cl. C12N 15/82 (2006.01)
CPC C12N 15/8213 (2013.01) [C12N 15/8216 (2013.01)] 14 Claims
 
1. A recombinant DNA construct comprising a 7SL promoter; operably linked to:
(i) a sequence encoding a single-guide RNA (sgRNA), or
(ii) a sequence specifying a non-coding RNA;
and wherein the sequence of said 7SL promotor comprises SEQ ID NO:174; or a fragment thereof, wherein the fragment is at least 140 bp in length, wherein the 7SL promotor or fragment thereof and the sgRNA or non-coding RNA come from different sources.